ArticleCancers2020
Development of Sensitive Droplet Digital PCR Assays for Detecting Urinary
Open access · goldAbstract read
In one paragraph
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 43 citations in OpenAlex.
- Review
- TERT promoter C228T and C250T mutation detection combined with cytology in the diagnosis of urothelial carcinomas: a real-world cohort study in a Chinese population.Cancer cell international · 2026Article
- Urinary bladder cancer needs more attention - recommendations for health care professionals and politicians in the European Union.Nature reviews. Urology · 2026Review
- The Diagnostic Performance of a Four-Gene Digital Droplet PCR Panel for Urine Liquid Biopsy in Urothelial Bladder Cancer.Diagnostics (Basel, Switzerland) · 2025Article
- Accuracy comparison of direct Sanger sequencing, immunohistochemistry, and droplet digital polymerase chain reaction in detectingAnnals of surgical treatment and research · 2025Article
- Diagnostic performance of Uromonitor and TERTpm ddPCR urine tests for the non-invasive detection of bladder cancer.Scientific reports · 2024Article
- Novel method for detecting frequent TERT promoter hot spot mutations in bladder cancer samples.Clinical and experimental medicine · 2024Article
- From Detection to Cure - Emerging Roles for Urinary Tumor DNA (utDNA) in Bladder Cancer.Current oncology reports · 2024Review
- Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease.Nature reviews. Urology · 2023Review
- Development of a Sensitive Digital Droplet PCR Screening Assay for the Detection ofBiomedicines · 2023Article
- TERT Promoter Mutations as Simple and Non-Invasive Urinary Biomarkers for the Detection of Urothelial Bladder Cancer in a High-Risk Region.International journal of molecular sciences · 2022Article
- Application of Droplet Digital PCR Technology in Muscular Dystrophies Research.International journal of molecular sciences · 2022Review
- Detection ofBiomedicines · 2022Review
- Urinary Exosomal Long Noncoding RNA TERC as a Noninvasive Diagnostic and Prognostic Biomarker for Bladder Urothelial Carcinoma.Journal of immunology research · 2022Article
- Construction of Molecular Subtype and Prognosis Prediction Model of Osteosarcoma Based on Aging-Related Genes.Journal of oncology · 2022Article
- Review
- Current and Emerging Applications of Droplet Digital PCR in Oncology: An Updated Review.Molecular diagnosis & therapy · 2022Review
- Urine TERT promoter mutations-based tumor DNA detection in patients with bladder cancer: A pilot study.Molecular and clinical oncology · 2021Article
- Prognostic Impact of the Combination ofJournal of neurosciences in rural practice · 2021Article
- Liquid Biopsy Biomarkers in Urine: A Route towards Molecular Diagnosis and Personalized Medicine of Bladder Cancer.Journal of personalized medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 7 institutions in 6 countries.
Md Ismail HosenInternational Agency for Research on Cancer (IARC), 69372 Lyon, France.ORCID 0000-0003-0862-7206
Nathalie ForeyInternational Agency for Research on Cancer (IARC), 69372 Lyon, France.
Geoffroy DurandInternational Agency for Research on Cancer (IARC), 69372 Lyon, France.
Catherine VoegeleInternational Agency for Research on Cancer (IARC), 69372 Lyon, France.
Selin BiliciInternational Agency for Research on Cancer (IARC), 69372 Lyon, France.
Patrice Hodonou AvogbeInternational Agency for Research on Cancer (IARC), 69372 Lyon, France.
Tiffany Myriam DelhommeInternational Agency for Research on Cancer (IARC), 69372 Lyon, France.ORCID 0000-0003-0265-4246
Matthieu FollInternational Agency for Research on Cancer (IARC), 69372 Lyon, France.ORCID 0000-0001-9006-8436
Arnaud ManelLe Creusot Hospital, 71200 Le Creusot, France.
Emmanuel VianDepartment of Urology, Protestant Clinic of Lyon, 69300 Caluire-et-Cuire, France.ORCID 0000-0002-5662-7254
Sonia MezianiInternational Agency for Research on Cancer (IARC), 69372 Lyon, France.
Berengere De TillyDepartment of Urology, Protestant Clinic of Lyon, 69300 Caluire-et-Cuire, France.
Gilles PoloDepartment of Urology, Protestant Clinic of Lyon, 69300 Caluire-et-Cuire, France.
Olesia LoleInternational Agency for Research on Cancer (IARC), 69372 Lyon, France.
Pauline FrancoisInternational Agency for Research on Cancer (IARC), 69372 Lyon, France.
Antoine BoureilleInternational Agency for Research on Cancer (IARC), 69372 Lyon, France.
Eduard PisarevFaculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, 119234 Moscow, Russia.ORCID 0000-0002-5764-3977
Andrei R O S E SalasInternational Agency for Research on Cancer (IARC), 69372 Lyon, France.ORCID 0000-0002-1565-5427
Sara Monteiro-ReisPortuguese Oncology Institute of Porto, Research Center (CI-IPOP), 4200-072 Porto, Portugal.ORCID 0000-0002-2193-2793
Rui HenriquePortuguese Oncology Institute of Porto, Research Center (CI-IPOP), 4200-072 Porto, Portugal.ORCID 0000-0003-3171-4666
Graham ByrnesInternational Agency for Research on Cancer (IARC), 69372 Lyon, France.
Carmen JeronimoPortuguese Oncology Institute of Porto, Research Center (CI-IPOP), 4200-072 Porto, Portugal.ORCID 0000-0003-4186-5345
Ghislaine SceloInternational Agency for Research on Cancer (IARC), 69372 Lyon, France.
James D McKayInternational Agency for Research on Cancer (IARC), 69372 Lyon, France.
Florence Le Calvez-KelmInternational Agency for Research on Cancer (IARC), 69372 Lyon, France.ORCID 0000-0003-0063-5068
Maria ZverevaInternational Agency for Research on Cancer (IARC), 69372 Lyon, France.ORCID 0000-0002-7432-1574
Centre international de recherche sur le cancer · FRInfirmerie Protestante · FRLomonosov Moscow State University · RUUniversidade do Porto · PTFaculdade de Ciências Médicas da Santa Casa de São Paulo · BRInstituto Português de Oncologia Francisco Gentil · PTUniversity of Dhaka · BD
Funding
World Health Organization 001
Abstract
Somatic mutations in the
Indexed as
bladder cancerdroplet digital PCRliquid biopsyTERT promoter mutationsurinary biomarkers
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.